Published: 3 February 2018
Author(s): B. Sposato, M. Scalese, M. Milanese, S. Masieri, C. Cavaliere, M. Latorre, N. Scichilone, A. Matucci, A. Vultaggio, A. Ricci, A. Cresti, P. Santus, A. Perrella, P.L. Paggiaro

Despite adding Omalizumab to conventional therapy, several severe asthmatics still show poor disease control. We investigated the factors that may affect a reduced Omalizumab response in a large population of severe asthmatics.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.